<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5606">
  <stage>Registered</stage>
  <submitdate>4/01/2012</submitdate>
  <approvaldate>4/01/2012</approvaldate>
  <nctid>NCT01505491</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetics and Safety Study of BI 695501 in Healthy Subjects</studytitle>
    <scientifictitle>Pharmacokinetics and Safety of BI 695501 in Healthy Subjects: a Randomized, Open-label, Single Dose, Parallel Arm, Active Comparator Clinical Phase I Study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>1297.1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - adalimumab
Treatment: drugs - BI695501
Treatment: drugs - adalimumab

Experimental: BI 695501 - Subject to receive one subcutaneous (s.c.) injection from a prefilled syringe containing BI 695501

Active Comparator: adalimumab - US - Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab

Active Comparator: adalimumab - EU - Subject to receive one s.c. injection from a prefilled syringe containing 40mg adalimumab


Treatment: drugs: adalimumab
40mg adalimumab single s.c. injection

Treatment: drugs: BI695501
BI 695501 single s.c injection

Treatment: drugs: adalimumab
40mg adalimumab single s.c. injection

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity</outcome>
      <timepoint>72 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum measured concentration of the analyte in plasma</outcome>
      <timepoint>72 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point</outcome>
      <timepoint>72 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 14</outcome>
      <timepoint>72 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal phase half life</outcome>
      <timepoint>72 days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent clearance of the analyte in the plasma after extravascular administration</outcome>
      <timepoint>72 days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          1. Healthy males

          2. Body mass index (BMI) =18.5 to =29.9 kg/m2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          1. Any clinically relevant abnormal finding of the medical examination (including blood
             pressure, pulse rate and electrocardiogram) deviating from normal and of clinical
             relevance

          2. Any evidence of a clinically relevant previous or concomitant disease as judged by the
             investigator.

          3. Chronic or relevant acute infections. A negative result for Human Immunodeficiency
             Virus, Hepatitis B and Hepatitis C testing is required for participation.

          4. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          5. Intake of prescribed or over-the-counter drugs with a long half-life (&gt;24 hours)
             within at least one month or less than 5 half-lives of the respective drug prior to
             administration or during the trial

          6. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)

          7. Inability to refrain from smoking during days of confinement at the study center

          8. Alcohol abuse (average more than 30 g/day)

          9. Current drug abuse</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>193</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/07/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Boehringer Ingelheim</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This trial will investigate the pharmacokinetics, safety and tolerability of BI 695501 and to
      establish pharmacokinetic equivalence of BI 695501 to adalimumab.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01505491</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Boehringer Ingelheim</name>
      <address>Boehringer Ingelheim</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>